摘要
Gd–chelate magnetic resonance imaging (MRI) contrast agents used in conventional clinical medicine still have some shortcomings, such as their low relaxation rates and poor imaging sensitivity. In this work, a Gd–chelate (Gd–DTPA), with a comparison made to the commercial contrast agent Magnevist was loaded into a zeolitic imidazolate framework (ZIF-8) to construct the efficient T 1 MRI contrast agent Gd–DTPA@ZIF-8. At 0.5 T, the longitudinal relaxivity value ( r 1 ) of Gd–DTPA@ZIF-8 reaches 29.60 mM −1 s −1 , which is about 6 times higher than that of Gd–DTPA. In terms of the retention of Gd–DTPA in ZIF-8, no obvious Gd 3+ ions are released in water and complete culture solution over a long time period. Haemolysis and cytotoxicity experiments revealed that Gd–DTPA@ZIF-8 has good biocompatibility. In addition, the in vivo MRI results prove that Gd–DTPA@ZIF-8 can significantly enhance the T 1 -weighted MRI contrast effect of the tumour site. These advantages make Gd–DTPA@ZIF-8 a potential candidate for biomedical applications.
危险品化学品经营许可证(带存储)